Moreover, in the mouse colon adenocarcinoma model, Naringenin induced more CD103 DC to infiltrate the tumor, promoted the CD8+ T cell activation, and enhanced the performance of the E7 vaccine against TC-1 mouse cancer treatment (80). The gene discussed is CD8A; the disease is colon adenocarcinoma.